.. CentraState chooses Cognizant to build up ICD-10 transition strategy Cognizant , a respected provider of it, consulting, and business process outsourcing services, today announced that it’s been selected by CentraState Healthcare System, a leading not-for-profit community health firm, to develop a technique for transitioning to ICD-10. As part of the engagement, Cognizant shall perform a thorough ICD-10 assessment to determine the clinical, administrative, and financial impact on business and IT processes, staff, and partners, and recommend an implementation strategy to enable a simple changeover to ICD-10 and meet up with the 2013 compliance deadline.Upon signature, CureVac gets EUR 35 million. Further, CureVac can perform milestone payments as high as EUR 430 million and royalties on sales. This new contract is component of Boehringer Ingelheim’s long-term dedication to delivering tomorrow’s tumor therapies through the discovery of novel treatment plans with high therapeutic worth for patients. Boehringer Ingelheim’s oncology pipeline addresses a broad selection of solid tumors and haematologic malignancies , including two investigational substances in Phase III scientific development: nintedanib in unique types of NSCLC and colorectal malignancy, and volasertib in severe myeloid leukemia. At Boehringer Ingelheim we are pleased with our commitment to greatly help enhance the treatment of cancers with a higher medical need.